Celon Pharma (WAR:CLN) Operating Margin %: -11.51% (As of Mar. 2026)


WAR:CLN Celon Pharma SA WAR:CLN
57 GF Score
Price zł19.52
GF Value zł22.51
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Celon Pharma Operating Margin %?

Celon Pharma WAR:CLN -2.30% 57 Operating Margin % is -11.51% as of Mar. 2026. GuruFocus rates WAR:CLN with a GF Score™ of 57/100 and a GF Value™ of zł22.51 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 955 Drug Manufacturers companies, Celon Pharma ranks worse than 78.32% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Celon Pharma's Operating Income for the three months ended in Mar. 2026 was zł-6.6 Mil. Celon Pharma's Revenue for the three months ended in Mar. 2026 was zł56.9 Mil. Therefore, Celon Pharma's Operating Margin % for the quarter that ended in Mar. 2026 was -11.51%.

The historical rank and industry rank for Celon Pharma's Operating Margin % or its related term are showing as below:

WAR:CLN' s Operating Margin % Range Over the Past 10 Years
Min: -23.47   Med: -4.97   Max: 36.41
Current: -8.74


WAR:CLN's Operating Margin % is ranked worse than
78.32% of 955 companies
in the Drug Manufacturers industry
Industry Median: 7.45 vs WAR:CLN: -8.74

Celon Pharma's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Celon Pharma's Operating Income for the three months ended in Mar. 2026 was zł-6.6 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was zł-14.0 Mil.


Celon Pharma  (WAR:CLN) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Celon Pharma Operating Margin % Related Terms


Celon Pharma Operating Margin % Historical Data

* Premium members only.

The historical data trend for Celon Pharma's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celon Pharma Operating Margin % Chart

Celon Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.02 -23.47 -18.86 -20.73 0.00

Celon Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -38.98 -34.16 9.93 0.00 -11.51

WAR:CLN vs ZTS, UTHR, VTRS: Operating Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celon Pharma Operating Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Celon Pharma's Operating Margin % falls into.


WAR:CLN
57GF Score
Celon Pharma SA WAR:CLN
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celon Pharma Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Celon Pharma's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-24.867 / 0
= %

Celon Pharma's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-6.553 / 56.928
=-11.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -11.51% mean?
Celon Pharma (WAR:CLN) has a Operating Margin % of -11.51% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Celon Pharma and its competitors. According to the industry distribution chart, Celon Pharma ranks #748 out of 955 companies in the Drug Manufacturers industry, placing it in the top 78.3%.
Is Celon Pharma's Operating Margin % too high?
Celon Pharma's current Operating Margin % is -11.51%. Based on the distribution chart, Celon Pharma ranks #748 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Celon Pharma has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's Operating Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Celon Pharma ranks #748 out of 955 companies for Operating Margin %. This places Celon Pharma in the lower half of its industry. The industry median Operating Margin % is 7.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.45, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Celon Pharma and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celon Pharma's current Operating Margin % is -11.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Based on GuruFocus' analysis, Celon Pharma (WAR:CLN) is currently considered Modestly Undervalued. The stock's GF Value™ is zł22.51, compared to a current price of zł19.52 — trading 13.3% below its estimated fair value. The current Operating Margin % is -11.51%. Celon Pharma's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Celon Pharma (WAR:CLN), the current Operating Margin % is -11.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celon Pharma (WAR:CLN) Overvalued in 2026?

Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued. The current stock price of zł19.52 is trading 13.3% below its estimated GF Value™ of zł22.51. GuruFocus considers Celon Pharma to be Modestly Undervalued.

Key valuation signals for WAR:CLN:

  • Operating Margin %: -11.51%
  • GF Value™: zł22.51 vs. price of zł19.52 (13.3% below fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the WAR:CLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Celon Pharma Business Description

Other Exchanges 8RP:Germany
Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
57GF Score

Get the complete analysis for WAR:CLN

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł19.52
Price
zł22.51
GF Value